MannKind Corporation (NASDAQ:MNKD) is one of the 13 Best Healthcare Stocks to Buy Under $10. On May 8, Wells Fargo analyst Tiago Fauth maintained a Buy rating on MannKind Corporation (NASDAQ:MNKD) and set a price target of $9.00.
A close-up of a doctor’s hand pressing on an inhaler, conveying the effect of the company’s therapeutic products.
The rating was based on the company’s promising growth potential and strategic advancements, as it is making notable progress in its MNKD-101 program, according to the analyst. With a majority of the expected sites activated and patients randomized, the interim analysis is set for mid-2026. The analyst expects the MNKD-101 program to advance in the second half of 2025.
Fauth also reasoned that MannKind Corporation (NASDAQ:MNKD) has strong revenue growth, supported by a potential expansion of Afrezza into the pediatric market and Tyvaso DPI royalties. When combined with the market’s focus on tangible revenue streams, these factors justify the analyst’s optimistic rating.
MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company that develops and commercializes innovative therapeutic devices and products that address serious unmet medical needs for endocrine and orphan lung diseases. The company’s pipeline and products include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.
While we acknowledge the potential of MNKD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
